TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29388085
Drug: Intra-articular HA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular HA (five injections every 7 days)
Study: 26928796
Drug: Control (Intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Intravenous saline infusion)
Study: 24132867
Drug: manualized dialectical-behavioral-therapy-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: manualized dialectical-behavioral-therapy-based group psychotherapy (GPT) plus methylphenidate (MPH)
Study: 24132867
Drug: manualized dialectical-behavioral-therapy-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: manualized dialectical-behavioral-therapy-based group psychotherapy (GPT) plus placebo (Plac)
Study: 20670909
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of virosomal-adjuvanted influenza vaccine (two doses of 0.50 mL 4 weeks apart)
Study: 20670909
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of virosomal-adjuvanted influenza vaccine (two doses of 0.25 mL 4 weeks apart)
Study: 12063152
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg/day) for 38 weeks followed by 12 weeks of placebo
Study: 12063152
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg/day) for 14 weeks followed by 36 weeks of placebo
Study: 2245435
Drug: Simvastatin, 20
Normalized name: Simvastatin, 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin, 20 mg od
Study: 2245435
Drug: Gemfibrozil, 600
Normalized name: Gemfibrozil, 600 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil, 600 mg bid
Study: 32861
Drug: Melperone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melperone (100 mg X 3)
Study: 32861
Drug: Thiothixene (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiothixene (10 mg X 3)
Study: 30327398
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiation therapy (SBRT) after standard chemotherapy, delivered in 15 fractions of 3-4.5 Gy.
Study: 30327398
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiation therapy (SBRT) after standard chemotherapy
Study: 21787207
Drug: Low-dose acitretin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose acitretin (approximately 25 mg/day)
Study: 21787207
Drug: High-dose acitretin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose acitretin (approximately 50 mg/day)
Study: 12575301
Drug: Dengzhanhua injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dengzhanhua injection (Group A)
Study: 12575301
Drug: Fufangdanshen injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fufangdanshen injection (Group B)
Study: 6420046
Drug: Corynebacterium parvum
Normalized name: Corynebacterium parvum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corynebacterium parvum and chemotherapy (C + I)
Study: 20486208
Drug: Hop intervention
Normalized name: HOPS
DrugBank: Hops (DB10687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hop intervention (2.04 mg XN, 1.20 mg IX, and 0.1 mg 8‐PN per supplement)
Study: 20486208
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no hop supplements)
Study: 11807724
Drug: AC polysaccharide
Normalized name: meningococcal AC polysaccharide (non-US)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC polysaccharide (MACP) vaccine
Study: 11807724
Drug: C conjugate
Normalized name: meningococcal C conjugate
Approvals — FDA: no, EMA: no, PMDA: no
Description: C conjugate (MCC) vaccine
Study: 10417495
Drug: Moclobemide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (150 mg twice daily)
Study: 1914366
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg aspirin with 64 mg caffeine
Study: 6312791
Drug: Soy polysaccharide
Normalized name: Soy polysaccharides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy polysaccharide (25 g/day)
Study: 6312791
Drug: Soy polysaccharide
Normalized name: Soy polysaccharides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy polysaccharide added to glucose solution
Study: 25100134
Drug: Sunitinib 50
Normalized name: sunitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 50 mg/day on a 4-week-on-2-week-off schedule
Study: 25100134
Drug: Sunitinib 37.5
Normalized name: sunitinib 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 37.5 mg/day continuous dosing
Study: 11049006
Drug: 0.8 g
Normalized name: Alcohol 0.8 g in 1 mL TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g x kg(‐1) ethanol (EOH) in young subjects
Study: 11049006
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg diazepam (DZ) in young subjects
Study: 11049006
Drug: 0.7 g
Normalized name: Bioflavonoid 700 MG/0.7 GM Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 g x kg(‐1) ethanol (EOH) in older subjects
Study: 11049006
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg diazepam (DZ) in older subjects
Study: 9313702
Drug: lexipafant (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: lexipafant (100 mg/day by continuous intravenous infusion for up to 7 days)
Study: 12959281
Drug: Frusemide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide (40 mg oral dose)
Study: 28920183
Drug: Regularly prescribed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regularly prescribed medications (average 5.6 medications per patient)
Study: 28920183
Drug: CIRS-G index
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIRS-G index measures
Study: 28920183
Drug: Polypharmacy (defined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypharmacy (defined as five or more concurrent medications)
Study: 26588662
Drug: Cabozantinib 40
Normalized name: cabozantinib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 40 mg daily with RT plus TMZ and post-RT TMZ
Study: 23553848
Drug: Cabozantinib 40
Normalized name: cabozantinib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 40 mg daily
Study: 26588662
Drug: Concurrent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent treatment arm
Study: 19229603
Drug: ivabradine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine therapy initiated at the time of hospital admission
Study: 15046281
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition admixtures exposed to ambient light for 24 hours
Study: 15046281
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition admixtures protected from ambient light for 24 hours
Study: 11913007
Drug: 10 weekly
Normalized name: donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 weekly sessions about healthy eating followed by 6 weekly sessions about exercise
Study: 11913007
Drug: 6 weekly
Normalized name: tobramycin 28 MG inhalation powder 56 Weekly Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 weekly sessions about exercise followed by 10 weekly sessions about healthy eating
Study: 9522325
Drug: High-levonorgestrel group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-levonorgestrel group: 2 mg estradiol valerate (days 1-21) + 0.25 mg levonorgestrel (days 12-21)
Study: 9522325
Drug: Low-levonorgestrel group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-levonorgestrel group: 2 mg estradiol valerate (days 1-21) + 0.15 mg levonorgestrel (days 10-21)
Study: 3117490
Drug: NORPLANT implants
Normalized name: Norplant 3-oxime
DrugBank: Norelgestromin (DB06713)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NORPLANT implants (first set)
Study: 3117490
Drug: NORPLANT implants
Normalized name: Norplant 3-oxime
DrugBank: Norelgestromin (DB06713)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NORPLANT implants (replacement set)
Study: 11225746
Drug: Buffered regular
Normalized name: INSULIN,REGULAR,HUMAN BUFFERED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered regular human insulin (Velosulin)
Study: 1444555
Drug: 5 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml/kg 20% albumin
Study: 1444555
Drug: 15 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml/kg 4.5% albumin
Study: 1444555
Drug: 15 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml/kg fresh frozen plasma
Study: 29727479
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 0.4 mg/kg per week
Study: 29727479
Drug: Ciclosporin (CyA)
Normalized name: ciclosporin
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ciclosporin (CyA) 4 mg/kg per day
Study: 25237463
Drug: Tamsulosin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.2 mg (group A)
Study: 25237463
Drug: Tamsulosin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.2 mg and solifenacin 5 mg (group B)
Study: 19508590
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (NP) infusion
Study: 19508590
Drug: Forearm balance
Normalized name: Rebalance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forearm balance of nitric oxide (NO) during ACh infusion
Study: 18229580
Drug: Steroid and
Normalized name: Corticosteroid and/or corticosteroid derivative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid and Xueshuantong
Study: 18229580
Drug: Steroid, DF‐521
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid, DF‐521 and Xueshuantong
Study: 8765697
Drug: Indomethacin hard-gelatin
Normalized name: Hard Gelatin Capsule Shell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin hard-gelatin capsule with saturated polyglycolysed glycerides (Gelucire)
Study: 8765697
Drug: Standard multiple-unit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard multiple-unit diffusion-controlled pellet capsule (reference formulation)
Study: 173814
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy alone (22 patients)
Study: 173814
Drug: Combined radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined radiation and drug therapy (19 patients)
Study: 27609785
Drug: 23/25 G
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23/25 G vitrectomy without any buckle (group E2)
Study: 15006955
Drug: Moxifloxacin (MXF),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (MXF), 400 mg
Study: 15006955
Drug: Levofloxacin (LEVO),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (LEVO), 500 mg daily for five doses
Study: 15006955
Drug: Azithromycin (AZI),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (AZI), 500 mg for one dose, then 250 mg daily for four doses
Study: 3707653
Drug: Ibopamine 50
Normalized name: ibopamine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine 50 mg t.i.d.
Study: 3358887
Drug: Vigabatrin 1
Normalized name: vigabatrin 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin 1 g
Study: 3358887
Drug: Vigabatrin 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin 2 g
Study: 3358887
Drug: Vigabatrin 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin 4 g
Study: 3358887
Drug: Vigabatrin 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin 2 g daily for 6 weeks
Study: 3358887
Drug: Vigabatrin 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin 3 g daily for 6 weeks
Study: 3358887
Drug: Post-treatment (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-treatment (1 week after stopping vigabatrin)
Study: 23253948
Drug: empagliflozin 50
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: empagliflozin 50 mg q.d. for 5 days with metformin 1,000 mg b.i.d. for 3 days and 1,000 mg q.d. on Day 4
Study: 23253948
Drug: metformin 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin 1,000 mg b.i.d. for 3 days and 1,000 mg q.d. on Day 4
Study: 21727662
Drug: Soy isoflavones
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavones (75 mg/day for 12 weeks)
Study: 16490805
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg aprepitant capsule on day 1 followed by 80 mg on days 2 and 3
Study: 16490805
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg and 80 mg aprepitant capsules administered in fed vs. fasted state
Study: 16490805
Drug: 3-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-day regimen of aprepitant (125 mg/80 mg/80 mg)
Study: 12721261
Drug: No endocrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No endocrine therapy
Study: 12721261
Drug: Endocrine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine treatment (Goserelin or Tamoxifen)
Study: 10714571
Drug: COL-1492 (52.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: COL-1492 (52.5 mg N-9 gel)
Study: 1303479
Drug: Cefoperazone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoperazone (1 gm per dose for 24 hours)
Study: 1303479
Drug: Ampicillin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin (500 mg per dose for 24 hours)
Study: 3919746
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of lysine acetyl salicylate (LAS)
Study: 30571406
Drug: No endovascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: No endovascular treatment (non-EVT)
Study: 26685004
Drug: mepolizumab (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: mepolizumab (100 mg, n = 9)
Study: 22647518
Drug: Elinogrel (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elinogrel (IV 80 or 120 mg followed by oral 50, 100, or 150 mg twice daily)
Study: 22647518
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 or 600 mg pre-procedure followed by 75 mg daily)
Study: 15916717
Drug: Isradipine (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (0 or 30 mg sustained release each evening prior to testing, plus 0 or 15 mg immediate release each morning 2 hours before cocaine infusion)
Study: 15916717
Drug: Intravenous cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cocaine (0, 0.325, and 0.650 mg/kg)
Study: 1976875
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and intravenous heparin
Study: 27451450
Drug: Bifidobacterium bifidum
Normalized name: Bifidobacterium Bifidum
DrugBank: Bifidobacterium bifidum (DB16538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium bifidum strain Bb (approximately one billion live cells daily for 4 weeks)
Study: 20823393
Drug: Adjunctive cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive cilostazol 100 mg twice daily (triple group; n=69)
Study: 20823393
Drug: High maintenance-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: High maintenance-dose clopidogrel 150 mg daily (high-MD group; n=65)
Study: 10021951
Drug: Spinal anaesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anaesthesia with 100 mg lidocaine 5% with 7.5% dextrose
Study: 10021951
Drug: Epidural anaesthesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural anaesthesia with 600 mg lidocaine 2%
Study: 7850821
Drug: Cilazapril (CLZ)
Normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril (CLZ) 5 mg plus Hydrochlorothiazide (HCTZ) 12.5 mg
Study: 7850821
Drug: Cilazapril (CLZ)
Normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril (CLZ) monotherapy
Study: 7850821
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 12.5 mg or 25 mg
Study: 2903182
Drug: Diazepam (≤30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (≤30 mg/day)
Study: 28232118
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg terbutaline via Turbuhaler® M2
Study: 28232118
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg terbutaline via Turbuhaler® M2
Study: 28232118
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg terbutaline via Turbuhaler® M3
Study: 28232118
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg terbutaline via Turbuhaler® M3
Study: 21492750
Drug: CMT (Chiropractic
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMT (Chiropractic Manipulative Therapy)
Study: 21492750
Drug: CMT +
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CMT + LLLT (Combination Therapy)
Study: 19059939
Drug: All-trans retinoic
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-trans retinoic acid (as an adjunct to intensive chemotherapy)
Study: 12792354
Drug: Treatment-naive patients
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-naive patients
Study: 17043836
Drug: Treatment-experienced patients
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-experienced patients
Study: 17043836
Drug: Nucleoside reverse
Normalized name: Non-nucleoside reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleoside reverse transcriptase inhibitors resistance
Study: 17043836
Drug: Non-nucleoside reverse
Normalized name: Non-nucleoside reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-nucleoside reverse transcriptase inhibitors resistance
Study: 17043836
Drug: Protease inhibitors
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitors resistance
Study: 12510813
Drug: IV neridronate
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV neridronate (100 mg infused intravenously for 30 minutes every 3 months)
Study: 2662738
Drug: Heparin (5,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (5,000 IU in bolus injection)
Study: 31991203
Drug: Kai-Xin-San (KXS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kai-Xin-San (KXS) treatment in DPs
Study: 31991203
Drug: Kai-Xin-San (KXS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kai-Xin-San (KXS) treatment in CUMS rats
Study: 22457321
Drug: Degarelix 240
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Degarelix 240 mg initial dose followed by 80 mg monthly maintenance
Study: 22457321
Drug: Degarelix 240
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Degarelix 240 mg initial dose followed by 160 mg monthly maintenance
Study: 16126052
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 50 mcg twice daily
Study: 16126052
Drug: Montelukast (MON)
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast (MON) 5 mg once daily
Study: 10068868
Drug: C-type natriuretic
Normalized name: C-type natriuretic peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-type natriuretic peptide (CNP) at pathophysiological plasma levels, intravenous infusion of synthetic human CNP-22 (2 pmol kg-1 min for 2 h)
Study: 31232712
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate therapy for 6 weeks
Study: 31232712
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate therapy for 6 months
Study: 24107876
Drug: Lacosamide (100-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacosamide (100-400 mg per day)
Study: 22036019
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg aspirin (per-protocol analysis for 258 participants)
Study: 22036019
Drug: Aspirin placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin placebo (per-protocol analysis for 250 participants)
Study: 22036019
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg aspirin (per-protocol analysis)
Study: 22036019
Drug: Aspirin placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin placebo (per-protocol analysis)
Study: 15669214
Drug: Serotonin noradrenaline
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin noradrenaline reuptake inhibitors (SNRIs)
Study: 8401618
Drug: Pefloxacin 800
Normalized name: pefloxacin
DrugBank: Pefloxacin (DB00487)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin 800 mg at the time of anaesthetic induction
Study: 30043582
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine in addition to conventional Western medicine
Study: 27228511
Drug: Epidural Steroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural Steroid Injections (ESIs)
Study: 24970708
Drug: Internet-based guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based guided self-help treatment (ICBT)
Study: 23427388
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) plus anti-infection and conventional medicine treatment
Study: 23427388
Drug: Anti-infection plus
Normalized name: gentian violet
DrugBank: Gentian violet cation (DB00406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-infection plus conventional medicine treatment
Study: 18720692
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (TAC) (20 mg)
Study: 8666599
Drug: Pneumatic plantar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumatic plantar compression and aspirin